DE69329367D1 - Wachstumshormon-enthaltendeproteinformulierung - Google Patents

Wachstumshormon-enthaltendeproteinformulierung

Info

Publication number
DE69329367D1
DE69329367D1 DE69329367T DE69329367T DE69329367D1 DE 69329367 D1 DE69329367 D1 DE 69329367D1 DE 69329367 T DE69329367 T DE 69329367T DE 69329367 T DE69329367 T DE 69329367T DE 69329367 D1 DE69329367 D1 DE 69329367D1
Authority
DE
Germany
Prior art keywords
growth hormone
pct
formulation
citrate
buffer substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69329367T
Other languages
English (en)
Other versions
DE69329367T2 (de
DE69329367T3 (de
Inventor
Staffan Castensson
Ebba Florin-Robertsson
Elvy Hoekby
Sirkka Thome
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20385860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69329367(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Publication of DE69329367D1 publication Critical patent/DE69329367D1/de
Publication of DE69329367T2 publication Critical patent/DE69329367T2/de
Application granted granted Critical
Publication of DE69329367T3 publication Critical patent/DE69329367T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69329367T 1992-04-03 1993-04-01 Wachstumshormon-enthaltende proteinformulierung Expired - Fee Related DE69329367T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9201073A SE9201073D0 (sv) 1992-04-03 1992-04-03 Protein formulation
SE9201073 1992-04-03
PCT/SE1993/000281 WO1993019776A1 (en) 1992-04-03 1993-04-01 Protein formulation comprising growth hormone

Publications (3)

Publication Number Publication Date
DE69329367D1 true DE69329367D1 (de) 2000-10-12
DE69329367T2 DE69329367T2 (de) 2001-06-21
DE69329367T3 DE69329367T3 (de) 2008-06-19

Family

ID=20385860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329367T Expired - Fee Related DE69329367T3 (de) 1992-04-03 1993-04-01 Wachstumshormon-enthaltende proteinformulierung

Country Status (15)

Country Link
US (1) US5567677A (de)
EP (1) EP0587858B2 (de)
JP (1) JP3268557B2 (de)
AT (1) ATE196092T1 (de)
AU (1) AU666007B2 (de)
CA (1) CA2102693C (de)
DE (1) DE69329367T3 (de)
DK (1) DK0587858T3 (de)
ES (1) ES2150940T5 (de)
GR (1) GR3034925T3 (de)
NO (1) NO310804B1 (de)
NZ (1) NZ251498A (de)
PT (1) PT587858E (de)
SE (1) SE9201073D0 (de)
WO (1) WO1993019776A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
ZA9711733B (en) 1996-12-31 1998-07-01 Monsanto Co Method for solubilization and naturation of somatotropins
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
CZ200260A3 (cs) * 1999-07-12 2002-04-17 Grandis Biotech Gmbh Formulace růstového hormonu
TWI283182B (en) * 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
WO2002092619A2 (en) * 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
EP1463752A4 (de) 2001-12-21 2005-07-13 Human Genome Sciences Inc Albuminfusionsproteine
CA2475953A1 (en) * 2002-02-27 2003-09-04 E. Ann Tallant Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
CN1668332A (zh) * 2002-07-09 2005-09-14 桑多斯股份公司 包含苯酚的含高浓度人生长激素的液体制剂
US20070065469A1 (en) * 2002-07-09 2007-03-22 Michael Betz Liquid formulations with high concentration of human growth hormone (high) comprising glycine
WO2004082707A2 (en) * 2003-03-18 2004-09-30 Ares Trading Sa Stabilisation of growth hormones in solution
WO2005063298A1 (en) 2003-12-23 2005-07-14 Pharmacia Corporation Stable growth hormone liquid formulation
UA89781C2 (uk) * 2004-04-07 2010-03-10 Арес Трейдінг С.А. Рідкий склад гормона росту
EP1781700B1 (de) 2004-08-03 2014-03-19 TransTech Pharma, LLC Rage-fusionsproteine und anwendungsverfahren
KR20070057818A (ko) * 2004-08-03 2007-06-07 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
JP4951344B2 (ja) * 2004-08-24 2012-06-13 第一三共株式会社 生理活性ペプチド液状製剤
ATE408624T1 (de) * 2004-11-09 2008-10-15 Ares Trading Sa Verfahren zur reinigung von fsh
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
CN101282990B (zh) * 2005-08-26 2013-04-03 阿雷斯贸易股份有限公司 糖基化干扰素-β的制备方法
EP1948221B1 (de) * 2005-11-02 2015-04-08 Syneron Medical Ltd. Pflasterzusammensetzungen mit humanem wachstumshormon
JP5199112B2 (ja) * 2005-12-09 2013-05-15 アレス トレーディング ソシエテ アノニム Ｆｓｈ又はｆｓｈ変異体を精製するための方法
ES2431632T3 (es) * 2005-12-23 2013-11-27 Gcoder Systems Ab Patrón de posicionamiento
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
EP2380983A3 (de) * 2006-05-05 2012-12-05 TransTech Pharma Inc. RAGE-Fusionsproteine, Formulierungen daraus und Verfahren zu ihrer Verwendung
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2009053360A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an fc-containing protein
AU2008314687A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying Fc-fusion proteins
WO2010122460A1 (en) 2009-04-20 2010-10-28 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
EP2427215A1 (de) * 2009-05-07 2012-03-14 Novo Nordisk Health Care AG Stabile pharmazeutische zusammensetzungen von mit einem oxim-linker derivatisiertem peptid
UA108994C2 (uk) * 2009-11-17 2015-07-10 Ипсен Фарма С.А.С. Фармацевтична композиція, що містить комбінацію hgh і rhigf-1, і процес її приготування (варіанти)
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
WO2015046974A1 (ko) * 2013-09-27 2015-04-02 한미약품 주식회사 지속형 인간 성장 호르몬 제제
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
US20160015789A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries, Ltd. FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
EP0189673B1 (de) * 1984-12-24 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Stabiles GRF-Präparat
PT83095B (en) * 1985-07-30 1987-12-23 Int Minerals & Chem Corp Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
ES2044941T5 (es) * 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
US4837202A (en) † 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH01308235A (ja) * 1988-06-03 1989-12-12 Yamanouchi Pharmaceut Co Ltd ヒト成長ホルモン経鼻剤
US5008244A (en) * 1989-05-15 1991-04-16 Pitman-Moore, Inc. Method for increasing fertility in animals
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
IN172427B (de) * 1989-11-14 1993-07-24 Fidia Spa
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
CA2636421C (en) † 1992-04-30 2010-06-29 Millennium Pharmaceuticals, Inc. A method of platelet and whole blood storage
ATE359824T1 (de) * 1992-07-31 2007-05-15 Genentech Inc Wässrige formulierung enthaltend menschliches wachstumshormon

Also Published As

Publication number Publication date
SE9201073D0 (sv) 1992-04-03
NO310804B1 (no) 2001-09-03
AU3913593A (en) 1993-11-08
CA2102693A1 (en) 1993-10-04
DE69329367T2 (de) 2001-06-21
JP3268557B2 (ja) 2002-03-25
US5567677A (en) 1996-10-22
EP0587858B2 (de) 2007-11-14
GR3034925T3 (en) 2001-02-28
NZ251498A (en) 1995-07-26
EP0587858B1 (de) 2000-09-06
CA2102693C (en) 2008-06-17
EP0587858A1 (de) 1994-03-23
JPH06508156A (ja) 1994-09-14
PT587858E (pt) 2001-02-28
NO934355L (no) 1993-12-01
AU666007B2 (en) 1996-01-25
ES2150940T5 (es) 2008-04-16
DK0587858T3 (da) 2000-12-18
NO934355D0 (no) 1993-11-30
ATE196092T1 (de) 2000-09-15
ES2150940T3 (es) 2000-12-16
DE69329367T3 (de) 2008-06-19
WO1993019776A1 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
DE69329367D1 (de) Wachstumshormon-enthaltendeproteinformulierung
EP0747092A3 (de) Lösungsflüssigkeit für durch Iontophorese zugeführte Medikamente
CA2275890A1 (en) Stable liquid interferon formulations
DE59504750D1 (de) Verfahren zur gewinnung von hochreinem von willebrand-faktor
IL135186A0 (en) LIQUID INTERFERON-β FORMULATIONS
PL274485A1 (en) Method of obtaining stable preparations of human proteins
DK0910399T3 (da) Stabilt farmaceutisk BDNF-præparat
ATE228005T1 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
ATE218868T1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
Holbrook et al. The identification of a peptide in human parotid saliva particularly active in enhancing the glycolytic activity of the salivary micro-organisms.
DK0641216T3 (da) Farmaceutisk præparat indeholdende IL-6
KR860006982A (ko) 안정한 감마 인터페론 제형의 제조방법
Donohue Jr et al. Glucose-6-phosphate dehydrogenase Partial characterization of the rat liver and uterine enzymes
Leaver Studies on certain peptide fractions isolated from human dentine
Lafeber Comparison of PTH and hypocalcin in mammalian and teleost bioassays
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA AB, STOCKHOLM, SE

8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: PFIZER HEALTH AB, STOCKHOLM, SE

8339 Ceased/non-payment of the annual fee